Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Payables (2016 - 2025)

Historic Payables for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $76000.0.

  • NovaBay Pharmaceuticals' Payables fell 8080.81% to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76000.0, marking a year-over-year decrease of 8080.81%. This contributed to the annual value of $609000.0 for FY2024, which is 3278.15% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Payables of $76000.0 as of Q3 2025, which was down 8080.81% from $604000.0 recorded in Q2 2025.
  • NovaBay Pharmaceuticals' Payables' 5-year high stood at $1.6 million during Q1 2022, with a 5-year trough of $76000.0 in Q3 2025.
  • Moreover, its 5-year median value for Payables was $947000.0 (2023), whereas its average is $916947.4.
  • Its Payables has fluctuated over the past 5 years, first tumbled by 8508.96% in 2021, then surged by 34711.54% in 2022.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Payables stood at $1.0 million in 2021, then increased by 3.35% to $1.1 million in 2022, then fell by 16.11% to $906000.0 in 2023, then crashed by 32.78% to $609000.0 in 2024, then tumbled by 87.52% to $76000.0 in 2025.
  • Its Payables stands at $76000.0 for Q3 2025, versus $604000.0 for Q2 2025 and $800000.0 for Q1 2025.